Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS)...

Related Keywords

United States ,Boston ,Massachusetts ,London ,City Of ,United Kingdom ,American ,America ,Wallstroeme Ofatumumab ,Sloan Simpson ,Jeffreya Cohen ,Prnewswire Novartis ,Julie Masow ,Marlena Abdinoor ,American Academy Of Neurology ,Twitter ,Novartis Pharmaceuticals Corporation ,Exchange Commission ,Novartis ,Glaxosmithkline ,National Ms Society ,Novartis Pharmaceuticals Corp ,Neurological Institute At Cleveland Clinic ,Nj Novartis Pharmaceuticals Corporation ,Genmab Press ,Sclerosis International Federation ,American Academy ,Annual Meeting ,Neurological Institute ,Victor Bult ,Innovative Medicines ,Novartis Pharmaceuticals ,Novartis Neuroscience ,Multifocal Leukoencephalopathy ,Infants Born ,Related Reactions ,East Hanover ,Pharmaceuticals Corporation ,Longer Term Ofatumumab Treatment ,Disability Worsening ,Brain Volume ,Year Safety ,People Living With Relapsing Multiple ,Adv Studies ,Sclerosis International ,Mapping Multiple Sclerosis Around ,Accessed August ,West Palm Beach ,Press Release ,